Voyager Therapeutics (NASDAQ:VYGR) Receives "Outperform" Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR - Free Report) in a report published on Tuesday,RTT News reports. They currently have a $9.00 price target on the stock, down from their prior price target of $11.00. Wedbush also issued estimates for Voyager Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.86) EPS.

Other analysts also recently issued reports about the stock. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They issued an "overweight" rating and a $5.73 target price on the stock. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 target price on the stock. Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a "buy" rating and a $12.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of "Buy" and a consensus price target of $15.72.

Voyager Therapeutics Stock Performance

Shares of VYGR stock traded down $0.15 during midday trading on Tuesday, reaching $4.23. 441,402 shares of the company were exchanged, compared to its average volume of 310,971. The company's 50 day moving average price is $5.57 and its two-hundred day moving average price is $6.27. Voyager Therapeutics has a 12 month low of $4.00 and a 12 month high of $10.66. The company has a market cap of $231.08 million, a P/E ratio of 5.96 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same period in the previous year, the firm earned ($0.59) EPS. As a group, sell-side analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 10,778 shares of company stock valued at $58,548. Corporate insiders own 4.53% of the company's stock.

Institutional Trading of Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC grew its position in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after acquiring an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after acquiring an additional 2,444 shares in the last quarter. Oxford Asset Management LLP bought a new stake in Voyager Therapeutics in the fourth quarter worth approximately $60,000. China Universal Asset Management Co. Ltd. grew its position in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after acquiring an additional 4,098 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Voyager Therapeutics in the third quarter worth approximately $74,000. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.